| Entry |
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Name | Trospium chloride (JAN/USP/INN); Spasmex (TN); Spasmoplex (TN) | ||||||||||
| Product | |||||||||||
| Generic | TROSPIUM CHLORIDE (A-S Medication Solutions), TROSPIUM CHLORIDE (Actavis Pharma), TROSPIUM CHLORIDE (Bluepoint Laboratories), TROSPIUM CHLORIDE (Bryant Ranch Prepack), TROSPIUM CHLORIDE (Bryant Ranch Prepack), TROSPIUM CHLORIDE (Bryant Ranch Prepack), TROSPIUM CHLORIDE (CIPLA USA INC.,), TROSPIUM CHLORIDE (Exelan Pharmaceuticals), TROSPIUM CHLORIDE (Glenmark Pharmaceuticals), TROSPIUM CHLORIDE (Golden State Medical Supply), TROSPIUM CHLORIDE (Granules Pharmaceuticals), TROSPIUM CHLORIDE (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals), TROSPIUM CHLORIDE (Major Pharmaceuticals), TROSPIUM CHLORIDE (Padagis US LLC), TROSPIUM CHLORIDE (Padagis US LLC), TROSPIUM CHLORIDE (Proficient Rx LP), TROSPIUM CHLORIDE (Slate Run Pharmaceuticals), TROSPIUM CHLORIDE ER (35573) | ||||||||||
| Formula | C25H30NO3. Cl | ||||||||||
| Exact mass | 427.1914 | ||||||||||
| Mol weight | 427.9636 | ||||||||||
| Structure |  | ||||||||||
| Simcomp | |||||||||||
| Class | Neuropsychiatric agent DG01491 Muscarinic cholinergic receptor antagonist | ||||||||||
| Remark |
| ||||||||||
| Efficacy | Overactive bladder agent, Muscarinic acetylcholine receptor antagonist | ||||||||||
| Comment | Treatment of urinary incontinence | ||||||||||
| Target | CHRM2 [HSA:1129] [KO:K04130] CHRM3 [HSA:1131] [KO:K04131] | ||||||||||
| Pathway |
| ||||||||||
| Interaction | |||||||||||
| Structure map |
| ||||||||||
| Brite | Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] G GENITO URINARY SYSTEM AND SEX HORMONES G04 UROLOGICALS G04B UROLOGICALS G04BD Urinary antispasmodics G04BD09 Trospium D01103 Trospium chloride (JAN/USP/INN) <US> USP drug classification [BR:br08302] Genitourinary Agents Antispasmodics, Urinary Trospium Chloride D01103 Trospium chloride (JAN/USP/INN) Drug groups [BR:br08330] Neuropsychiatric agent DG01491 Muscarinic cholinergic receptor antagonist D01103 Trospium chloride Target-based classification of drugs [BR:br08310] G Protein-coupled receptors Rhodopsin family Acetylcholine (muscarinic) CHRM2 D01103 Trospium chloride (JAN/USP/INN) <US> CHRM3 D01103 Trospium chloride (JAN/USP/INN) <US> New drug approvals in the USA [br08319.html] New molecular entities and new therapeutic biological products D01103 New drug approvals in the USA, Europe and Japan [br08328.html] Approval dates by FDA, EMA and PMDA D01103 | ||||||||||
| Other DBs |
| ||||||||||
| KCF data | ATOM 30 1 X Cl 11.7779 -16.5523 #- 2 N2y N 14.0700 -15.8200 #+ 3 C1x C 15.1900 -14.9800 4 C1x C 14.7700 -13.6500 5 C1x C 13.3700 -13.6500 6 C1x C 12.9500 -15.0500 7 O7a O 18.1300 -19.5300 8 C1y C 17.4300 -18.3400 9 C1x C 16.3800 -16.8000 10 C1x C 16.3800 -17.8500 11 C1y C 14.9100 -16.8000 12 C1y C 14.8400 -17.8500 13 C1x C 13.8600 -17.3600 14 C1x C 13.3700 -18.4800 15 C7a C 19.5300 -19.5300 16 O6a O 20.2300 -20.7424 17 C1d C 20.2300 -18.3176 18 C8y C 21.8398 -18.3176 19 C8y C 19.5396 -17.1221 20 O1a O 20.9300 -17.1051 21 C8x C 20.2251 -15.9347 22 C8x C 19.5250 -14.7223 23 C8x C 18.1250 -14.7224 24 C8x C 17.4396 -15.9097 25 C8x C 18.1396 -17.1221 26 C8x C 22.5497 -19.5468 27 C8x C 23.9497 -19.5466 28 C8x C 24.6496 -18.3341 29 C8x C 23.9397 -17.1049 30 C8x C 22.5397 -17.1051 BOND 33 1 3 4 1 2 8 9 1 3 8 10 1 4 9 11 1 5 10 12 1 6 11 2 1 7 11 13 1 8 12 14 1 9 12 2 1 10 13 14 1 11 8 7 1 #Down 12 4 5 1 13 5 6 1 14 6 2 1 15 2 3 1 16 7 15 1 17 15 16 2 18 15 17 1 19 17 18 1 20 17 19 1 21 17 20 1 22 19 21 2 23 21 22 1 24 22 23 2 25 23 24 1 26 24 25 2 27 19 25 1 28 18 26 2 29 26 27 1 30 27 28 2 31 28 29 1 32 29 30 2 33 18 30 1 |